Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/20597
Título
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group.
Autor(es)
Sargas, Claudia | Ayala, Rosa | Larráyoz, María J | Chillón, María C | Rodriguez-Arboli, Eduardo | Bilbao, Cristina | Prados de la Torre, Esther | Martínez-Cuadrón, David | Rodríguez-Veiga, Rebeca | Boluda, Blanca | Gil, Cristina | Bernal, Teresa | Bergua, Juan | Algarra, Lorenzo | Tormo, Mar | Martínez-Sánchez, Pilar | Soria, Elena | Serrano, Josefina | Alonso-Dominguez, Juan M | García, Raimundo | Amigo, María Luz | Herrera-Puente, Pilar | Sayas, María J | Lavilla-Rubira, Esperanza | Martinez-Lopez, Joaquin CNIO | Calasanz, María J | García-Sanz, Ramón | Pérez-Simón, José A | Gómez Casares, María T | Sánchez-García, Joaquín | Barragán, Eva | Montesinos, Pau
Fecha de publicación
2023-05-12
Cita
Blood Cancer J . 2023;13(1):77.
Idioma
Inglés
Tipo de documento
journal article
Resumen
Next-Generation Sequencing is needed for the accurate genetic risk stratification of acute myeloid leukemia according to European LeukemiaNet (ELN) guidelines. We validated and compared the 2022 ELN risk classification in a real-life cohort of 546 intensively and 379 non-intensively treated patients. Among fit patients, those aged ≥65 years old showed worse OS than younger regardless risk classification. Compared with the 2017 classification, 14.5% of fit patients changed the risk with the 2022 classification, increasing the high-risk group from 44.3% to 51.8%. 3.7% and 0.9% FLT3-ITD mutated patients were removed from the favorable and adverse 2017 categories respectively to 2022 intermediate risk group. We suggest that midostaurin therapy could be a predictor for 3 years OS (85.2% with vs. 54.8% without midostaurin, P = 0.04). Forty-seven (8.6%) patients from the 2017 intermediate group were assigned to the 2022 adverse-risk group as they harbored myelodysplasia (MDS)-related mutations. Patients with one MDS-related mutation did not reach median OS, while patients with ≥2 mutations had 13.6 months median OS (P = 0.002). Patients with TP53 ± complex karyotype or inv(3) had a dismal prognosis (7.1 months median OS). We validate the prognostic utility of the 2022 ELN classification in a real-life setting providing supportive evidences to improve risk stratification guidelines.
MESH
Versión en línea
DOI
Aparece en las colecciones
Ficheros en el ítem
![Acceso Abierto Acceso Abierto](/themes/Mirage2/images/openAccess.png)
- Nombre:
- TREM2 macrophagesdriveNKcellpa ...
- Tamaño:
- 2.719Mb
- Formato:
- Descripción:
- Artículo principal
![Acceso Abierto Acceso Abierto](/themes/Mirage2/images/openAccess.png)
- Nombre:
- 41408_2023_835_MOESM1_ESM.pdf
- Tamaño:
- 1.110Mb
- Formato:
- Descripción:
- Supplementary information
Este Item está sujeto a una licencia Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Ítems relacionados
Mostrando ítems relacionados por Título, autor o palabras clave.
-
2023-01
research article
Monge Corella, Susana ISCIII; Latasa Zamalloa, Pello; Sierra Moros, María José; et al.